Floatz logo

ENCENICLINE

Cognition

FORUM Pharmaceuticals IncSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

150 Active assets in the Cognition cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
Metformin
Fudan University
Phase 4BB

View all 50 →

Same molecule, other indications

ENCENICLINE is also rated in:

Impaired CognitionDormant
BB
Indicative ·
66 / 100
View asset →
central nervous system disorderDormant
BB
Indicative ·
64 / 100
View asset →
schizophreniaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →